上海交通大学医学院附属瑞金医院感染科主任医师、博士生导师。获上海市公共卫生优秀学科带头人，上海市科技一等奖、上海市医学科技一等奖、华夏医学科技一等奖、中华医学科技三等奖。主持国家自然科学基金、上海市医学发展基金重点研究项目、上海市科学技术委员会、市教委、市卫计委重点课题以及“十一五”、“十二五”、“十三五”国家科技攻关子课题多项。 部分论著如下： 1. Ding Y, Feng M, Ma D, Zhao G, Wang X, An B, Xu Y, Lou S, Lin L, Xie Q, Liu K, Bao S, Wang H. The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China. Front Oncol. 2023 Mar 14;13:1109980. (通讯作者) 2. Lou S, Cao Z, Chi W, Wang X, Feng M, Lin L, Ding Y, Liu K, Qu L, Zhao G, Bao S, Wang H. The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB. Front Pharmacol. 2023 Apr 24;14:1164309. (通讯作者) 3. Liu K, Ding Y, Wang Y, Zhao Q, Yan L, Xie J, Liu Y, Xie Q, Cai W, Bao S, Wang H. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma. Clin Exp Med. 2023 Jun;23(2):397-409. (通讯作者) 4. Liu K, Ding Y, Xu Y, Tang W, Feng M, Liu Y, Bao S, Wang H. AL amyloidosis with primary presentation of multiple serous cavity effusion and severe cholestasis: a case report and review of literature. BMC Gastroenterol. 2022 Mar 18;22(1):128. (通讯作者) 5. Wu S, Wang X, Feng M, Liu X, Fan X, Ran X, Wang B, Wang H. Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer-based COVID-19 vaccine ZF2001 in chronic hepatitis B patients. Front Med (Lausanne). 2023 Feb 8;10:1078666. (通讯作者) 6. Feng M, Liu K, Zhao G, Lou S, An B, Lin L, Ding Y, Bao S, Wang H. A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN. Antiviral Res. 2022 Jun;202:105315. (通讯作者) 7. Zhao Q, Liu K, Zhu X, Yan L, Ding Y, Xu Y, Lou S, Zhao G, Xie Q, Gao Y, Bao S, Wang H. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Res. 2020 Dec;184:104953. doi: 10.1016/j.antiviral.2020.104953. (通讯作者) 8. Chen L, Cao Z, Yan L, Ding Y, Shen X, Liu K, Xiang X, Xie Q, Zhu C, Bao S, Wang H, Circulating receptor-Interacting protein kinase 3 are increased in HBV patients with acute-on-chronic liver failure and are associated with clinical outcome, Front Physiol,2020,11,526. DOI:10.3389/fphys.2020.00526.（通讯作者） 9. Wang X, Chen L, Wang H, Cai W, Xie Q, Modulation of bile acid profile by gut microbiota in chronic hepatitis B，J. Cell. Mol. Med. 2020,24(4):2573-2581. DOI：10.1111/jcmm.14951.（共同通讯作者） 10. Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X, Yan L, Cao Z, Xie Q, Zhu C, Bao S, Wang H, Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma, Cancer Med,2020,9(9):3057-3069. DOI:10.1002/cam4.2968.（通讯作者） 11. Xu Y, Cao Z, Ding Y, Li Z, Xiang X, Lai R, Sheng Z, Liu Y, Cai W, Hu R, Wang H, Xie Q, Long non-coding RNA NEAT1 alleviates acute-on-chronic Liver failure through blocking TRAF6 mediated inflammatory response, Frontiers in physiology, 2019.10:1503. DOI:10.3389/fphys.2019.01503.（共同通讯作者） 12. Liu K, Chen L, Zhao G, Cao Z, Li F, Lin L, Zhu C, Xie Q, Xu Y, Bao S, Wang H, IPS-1 polymorphisms in regulating interferon response in HBV infection. Biosci Trends,2019,13(2):130-135.（通讯作者） 13. Cao Z, Chen L, Li J, Liu Y, Bao R, Liu K, Yan L, Ding Y, Guo Q, Xiang X, Xie J, Lin L, Xie Q, Bao S, Wang H, Serum keratin-18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virus-related cirrhosis, J Viral Hepat,2019,26 (7):835-845.（通讯作者） 14. Yan L, Zhu C, Li J, Chen L, Ding Y, Cao Z, Liu K, Lin L, Tang W, Xie Q, Xu Y, Bao S, Wang H. Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients, Infect Drug Resist, 2018,11:2001-2009.（通讯作者） 15. Chen L, C Zhu, F Li, Wang Y, Bao R, Cao Z, Xiang X, Yan L, Lin L, Zhao G, Xie Q, Bao S, Wang H. Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients. Cell Biosci. 2018;8:14.（通讯作者）